systemic lupus erythematosus (SLE). Systemic lupus erythematosus
Conditions
Interventions
Intervention 1: patients with SLE as case group were referred to Imam Reza immunology clinic and at baseline a complete history-taking and physical examination was done. Informed consent was obtained
Sanofi Pasteur MSD). After vaccinations patients were observed at clinic for 30 minute by rheumatologist and adverse effects such as severe local swelling and redness, fever or weakness were recorded.
Prevention
patients with SLE as case group were referred to Imam Reza immunology clinic and at baseline a complete history-taking and physical examination was done. Informed consent was obtained from all partici
patients with asthma as control group were referred to Imam Reza immunology clinic. Informed consent was obtained from all participants or their parents. Before vaccination 5 cc venous blood sample wa
Sponsors
Shiraz University of Medical Science
Eligibility
Sex/Gender
All
Age
2 Years to 18 Years
Inclusion criteria
Inclusion criteria: inclusion criteria of case group: 2-18 years old; SLE disease exclusion criteria of case group: fever; recent immunization; history of previous pneumococcal vaccination; history of hypersensitivity reaction to vaccination; platelet level less than 50,000 ; mixed connective tissue disorders; IVIG injection in last 3 months. inclusion criteria of control group: 2-18 years old; mild asthma exclusion criteria of control group: fever; recent immunization; history of previous pneumococcal vaccination; history of hypersensitivity reaction to vaccination; platelet level less than 50,000 ; mixed connective tissue disorders; IVIG injection in last 3 months; patients with persistent or severe asthma; patients with history of immunosuppressive therapy or PO corticosteroid consumption; patient with history of other immunodeficiency disorders
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Speific anti-pneumococcal antibody. Timepoint: before vaccination and 3 weeks after intervention. Method of measurement: using enzyme linked immunoassay kit specific for pneumococcal vaccine (ELISA).;Lupus activity. Timepoint: before vaccination and 3 weeks after intervention. Method of measurement: according to SLE disease activity index (SLEDAI). | — |
Secondary
| Measure | Time frame |
|---|---|
| SLE activity. Timepoint: before vaccination and 3 weeks after intervention. Method of measurement: according to SLE disease activity index. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Soheila Alyasin
Shiraz University of Medical Science
Outcome results
None listed